Sarepta Elevidys Safety Concerns - Search News

Order byBest matchMost fresh

News

FDA, Sarepta

FDA allows Sarepta to resume some Elevidys shipments

The company can again ship the Duchenne gene therapy for patients who can still walk, following a one-week pause triggered by safety concerns.

Continue reading

Fierce Pharma · 4h

FDA takes U-turn on Sarepta’s Elevidys, backing Duchenne gene therapy again in ambulatory patients

BioSpace · 13h

Sarepta Denies Latest Patient Death is Elevidys-Linked as FDA Launches Probe

12hon MSN

Sarepta rises 2%; Barclays downgrades to underweight on liquidity and Elevidys concerns

Sarepta Therapeutics (NASDAQ:SRPT) shares dropped sharply premarket on Monday before paring losses as Barclays revised its ...

Fierce Biotech7d

Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy

The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb-girdle ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results